Skip to content
Toggle navigation
Sign Up
Contact
Twitter
LinkedIn
Search
Search
About CARB-X
Overview
Global Threat
Our Strategy
Stewardship and Access
Management & Staff
Joint Oversight Board
Advisory Board
Careers
Annual Reports
Boston University
Portfolio
Portfolio Product Developers
Portfolio-Pipeline
CARB-X Graduates
Spotlight on Science
Portfolio Acceleration Tools
Partners
Funding Partners
Global Accelerator Network
Apply
2022-2023 Funding Themes
Omnibus Solicitation
Omnibus Outcomes
Resources
CARB-X Connect
Presentations
Videos
Publications
Education
PD Resources
Media Resources
AMR Test Directory
News
CARB-X News
Recommended News
In the News
Antibiotic Resistance
Events
About CARB-X
Overview
Global Threat
Our Strategy
Stewardship and Access
Management & Staff
Joint Oversight Board
Advisory Board
Careers
Annual Reports
Boston University
Portfolio
Portfolio Product Developers
Portfolio-Pipeline
CARB-X Graduates
Spotlight on Science
Portfolio Acceleration Tools
Partners
Funding Partners
Global Accelerator Network
Apply
Funding Themes
Omnibus Solicitation
Application Process (2022-2023)
Entering Portfolio
Applicant Questions (2019)
Resources
Presentations
Videos
Publications
Education
PD Resources
Media Resources
AMR Test Directory
News
CARB-X News
Recommended News
In the News
Antibiotic Resistance
Events
Contact
Legal
News
Antibiotics aren’t profitable enough for Big Pharma to make more
Antibiotics aren’t profitable enough for Big Pharma to make more
Full Story
Toggle navigation
Toggle navigation